Peyronie Disease Clinical Trial
Official title:
Does Size Matter: A Single Case Experimental Design of Limiting the Depth of Penetration During Intercourse
Our hypothesis is that reducing the length of the penis does not lead to loss of sexual satisfaction or emotional closeness in the female partner. This will be investigated by a single case experimental design in 12 couples.
The investigators will conduct a single case experimental design (SCED), in which a woman
acts as her own control with a reversal design between randomly allocated phases. These
include a control phase (A) and phases with various sizes of penile rings (B, C, and D).
The male participant will be asked to measure the length and girth of their erect penis using
standardized instructions and flexible tape measure before the start of the experiment. This
will partly determine the inner circumference of the ring provided. The male participant will
be given instructions on how to use the penile rings and ensure that the female participant
is blind to the size of the ring used.
There will be randomization (a) to the phase (the size of ring) and (b) the number of times
of intercourse within a phase. The male partner will be blind to ratings made by the female
partner. There is no carry over effect from one phase to another. The randomization of the
phase means less guessing of the size of the ring, and less interaction with moderators (e.g.
menstrual cycle, alcohol, holiday or life events randomly spread across phases). In a SCED,
one then replicates in Case 2, Case 3 etc and a meta-analysis is conducted of all the single
cases.
Randomisation will occur to either
1. Phase A "Normal" intercourse with very thin (less than 0.5cm) ring randomised to either
3, 4 or 5 episodes of intercourse)
2. Phase B - 1" ring randomised to either 3, 4, or 5 episodes of intercourse)
3. Phase C - 1.5" ring randomised to either 3, 4, or 5 episodes of intercourse)
4. Phase D - 2" ring randomised to either 3, 4, or 5 episodes of intercourse) The male
partner will be kept informed by text or email or phone (whichever is convenient) of
when to change the size of ring and the number of times it should be used. The female
partner will be asked to be blind to the size of ring used after each episode of
intercourse. Blindness will be tested by asking if the female partner "saw" the size of
the ring or whether she was able to guess when a change in the size of the ring
occurred.
Measures:
The investigators will use a Visual Analogue Scale (0-100) for the female participant ratings
of (a) sexual pleasure and (b) how emotionally connected she felt to her partner (c) any
adverse experiences.
The female participant will be asked to rate the degree of change (positive or negative) that
would be significant for them e.g. a drop of rating 65 to 45) The female participant will be
asked to rate satisfaction and emotional closeness as soon as possible after intercourse. The
investigators will ask all participants to enter the data directly onto web based capture of
data. This will be anonymized so that they will be identified by a character.
The male participant will be asked to confirm the size of the ring used and any other
comments.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03774264 -
Treatment Response to Xiaflex for Men With Peyronie's Disease
|
||
Recruiting |
NCT05777031 -
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease
|
Phase 4 | |
Active, not recruiting |
NCT05871177 -
Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD)
|
N/A | |
Recruiting |
NCT05768867 -
French Translation and Validation of the PEYronie's Disease QUESTionnaire
|
||
Recruiting |
NCT04512287 -
PRP for Treatment of Peyronie's Disease
|
Phase 2 | |
Withdrawn |
NCT05646602 -
Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction
|
N/A | |
Recruiting |
NCT03530540 -
Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease.
|
N/A | |
Recruiting |
NCT06303661 -
Non-ablative Radiofrequency and Low Intensity Shock Wave Therapy in Fibrotic Plaque in Men With Peyronie's Disease
|
N/A | |
Recruiting |
NCT06065436 -
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
|
N/A | |
Recruiting |
NCT05316714 -
Novel Nanofat Regenerative Surgical Technique for Peyronies' Disease Treatment
|
N/A | |
Completed |
NCT04370652 -
Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum
|
||
Active, not recruiting |
NCT05480683 -
Pelvic CT With Agatston Calcium Score for Peyronie Disease
|
N/A | |
Recruiting |
NCT04821115 -
Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease
|
N/A |